From failure to meet the clinical endpoint to US Food and Drug Administration approval: 15th antisense oligonucleotide therapy approved Qalsody (tofersen) for treatment of SOD1 mutated amyotrophic lateral sclerosis

Author(s):: Roon-Mom, W. van; Ferguson, C.; Aartsma-Rus, A.

Published: 2023
Publication type: Article / Letter to editor

Date issued: 2023-08-01
Language: English
Publisher: MARY ANN LIEBERT, INC
Is part of: Nucleic Acid Therapeutics (2023), Vol. 33, no. 4, p. 234-237
hdl: 1887/3764358
doi: 10.1089/nat.2023.0027
URL: https://www.liebertpub.com/doi/10.1089/nat.2023.0027